• The problem of preeclampsia is far from being solved

The problem of preeclampsia is far from being solved

HEALTH OF WOMAN. 2017.1(117):25–30

Veropotvelyan P., Radchenko V., Tsehmistrenko I., Rusak N., Gnilusha I.                                
«Interregional centre of medical genetics and prenatal diagnosis», Krivoy Rog
FPE «Dnipropetrovsk medical Academy», Krivoy Rog
Perinatal center, Kiev
PI «Kryvyi Rih city maternity hospital № 1» DOS»

A review of the literature on prognostic factors of development of pre-eclampsia and endothelial dysfunction in the maternal circulation is done. It is drawn attention to one of the last work on the prediction of preeclampsia for 1 week, as well as the risk of developing this pathology during 4 weeks (investigation PROGNOSIS) on the basis of the determination of the value of the ratio of sFlt-1 / PlGF. The threshold point ratio of sFlt-1 / PlGF which is equal to 38 has important prognostic value. The value of sFlt-1 / PlGF is 38 or less had a negative predictive value of 99.3% and above 38 lead to the development of preeсlampsia for 4 weeks in 36.7%. The ratio of soluble fms like tyrosine kinase-1 in placental growth factor can be considered as a non-invasive predictor of preeclampsia.

Key words: preeclampsia, soluble fms-like tyrosine kinase-1, placental growth factor, angiogenesis.

REFERENCES

1. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. 2011. Prediction of early, intermediate and late pre-eclampsia from ma temal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn 31;1:66–74. https://doi.org/10.1002/pd.2660; PMid:21210481

2. Anderson UD, Olsson MG, Kristensen KH, Вkerstmm B, Hansson SR. 2012. Review: Biochemical markers to predict preeclampsia. Placenta 33;Suppl:42–47.

3. Álvarez-Fernández I, Prieto B, Rodríguez V, Ruano Y, Escudero AI, Álvarez FV. 2014. New biomarkers in diagnosis of early onset preeclampsia and imminent delivery prognosis. Clin. Chem. Lab. Med. 52(8):1159–68. https://doi.org/10.1515/cclm-2013-0901; PMid:24516004

4. Audibert E, Boucoiran I, An N, Aleksandrov N, Delvin E, Bujold E, Rey E. 2010. Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. Am J Obstet Gynec 203;4:383.el-8.

5. Benzing Т. Hypertension: Testing for pre-eclampsia: paving the way to early diagnosis. Nature Reviews Nephrology 02.2016.

6. Brosens I, Pijnenborg R, Vercruysse L, Romero R. 2011. The «Great Obstetrical Syndromes» are associated with disorders of deep placentation. Am J Obstet Gynec 204;3:193–201. https://doi.org/10.1016/j.ajog.2010.08.009; PMid:21094932 PMCid:PMC3369813

7. Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, Mackillop L et al. 2013. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation. 128(19):2121–31. https://doi.org/10.1161/circulationaha.113.003215

8. Chaiworapongsa T, Chaemsaithong P, Yeo L, Romero R. 2014. Pre-eclampsia. Part 1: current understanding of its pathophysiology. Nat. Rev. Nephrol. 10:466–80. https://doi.org/10.1038/nrneph.2014.102; PMid:25003615

9. Chaiworapongsa T, Romero R, Kim YM et al. 2005. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 17:3–18. https://doi.org/10.1080/14767050400028816; PMid:15804781

10. Cnossen JS, Morris RK, ter Riet G, Mol BW, van der Post JA, Coomarasamy A, Zwinderman AH, Robson SC, Bindels PJ, Kleijnen J, Khan KS. 2008. Use of uterine artery Doppler ultrasonogra phy to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ 178;6:701–711. https://doi.org/10.1503/cmaj.070430; PMid:18332385 PMCid:PMC2263112

11. De Vivo A, Baviera G, Giordano D, Todarello G, Corrado E, Anna R. 2008. Endoglin. P1GF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynec Scand 87;8:837–842. https://doi.org/10.1080/00016340802253759; PMid:18607829

12. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE. 2003. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111;5:707–716. https://doi.org/10.1172/JCI17423; PMid:12618525 PMCid:PMC151905

13. Grill S, Rusterholz C, Zanetti-Dдllenbach R et al. 2009. Potential markers of preeclampsia – a review. J Reprod Biol Endocrinol 7:70. https://doi.org/10.1186/1477-7827-7-70; PMid:19602262 PMCid:PMC2717076

14. Holmes VA, Young IS, Patterson CC, Maresh MJ, Pearson DW, Walker JD, McCance DR. 2013. Diabetes and Preeclampsia Intervention Trial (DAPIT) Study Group. The role of angiogenic and antiangiogenic factors in the second trimester in the prediction of preeclampsia in pregnant women with type 1 diabetes. Diabetes Care. 36(11):3671–7. https://doi.org/10.2337/dc13-0944; PMid:23920083 PMCid:PMC3816852

15. Husse S, Gottschlich A, Schrey S, Stepan H, Hoffmann J. 2014. Predictive value of the sFlt1/PlGF ratio for the diagnosis of preeclampsia in high-risk patients. Z. Geburtshilfe Neonatol. 218(1):34–41. PMid:24595913

16. Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E et al. 2009. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J. Matern. Fetal Neonatal Med. 22(11):1021–38. https://doi.org/10.3109/14767050902994754; PMid:19900040 PMCid:PMC3427777

17. Kvehaugen AS, Dechend R, Ramstad HB, Troisi R, Fugelseth D, Staff AC. 2011. Endothelial function and circulating biomarkers are disturbed in women and children after preeclampsia. Hypertension. 58(1):63–9. https://doi.org/10.1161/HYPERTENSIONAHA.111.172387; PMid:21606387

18. Lai J, Garcia-Tizon Larroca S, Peeva G, Poon LC, Wright D, Nicolaides KH. 2014. Competing risks model in screening for pre-eclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks’ gestation. Fetal Diagn. Ther. 35(4):240–8. https://doi.org/10.1159/000359968; PMid:24853452

19. Lamarca B. 2012. Endothelial dysfunction. An important mediator in the pathophysiology of hypertension during pre-eclampsia. Minerva Ginecol. 64(4):309-20. PMid:22728575 PMCid:PMC3796355

20. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF et al. 2004. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350(7):672–83. https://doi.org/10.1056/NEJMoa031884; PMid:14764923

21. Maharaj AS, Walshe TE, Saint-Geniez M, Venkatesha S, Maldonado AE, Himes NC, Matharu KS, Karumanchi SA, D’Amore PA. 2008. VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med 205;2:491–501. https://doi.org/10.1084/jem.20072041; PMid:18268040 PMCid:PMC2271023

22. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S et al. 2003. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111(5):649–58. https://doi.org/10.1172/jci17189

23. Moore Simas TA, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard SE. 2007. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am. J. Obstet. Gynecol. 197(3):244. e1–8.

24. Myers JE, Kenny LC, McCowan LM, Chan EH, Dekker GA, Poston L, Simpson NA, North RA. 2013. SCOPE consortium. Angiogenic factors combined with clinical risk factors to predict preterm preeclampsia in nulliparous women: a predictive test accuracy study. BJOG 120;10:1215–1223. https://doi.org/10.1111/1471-0528.12195; PMid:23906160

25. Odibo AO, Zhong Y, Goetzinger KR, Odibo L, Bick JL, Bower CR, Nelson DM. 2011. First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of preeclampsia. Placenta 32;8:598–602. https://doi.org/10.1016/j.placenta.2011.05.006; PMid:21652068 PMCid:PMC3142303

26. Olsson MG, Olofsson T, Tapper H, Akerstrom B. 2008. The lipocalin alpha1-microglobulin protects erythroid K562 cells against oxidative damage induced by heme and reactive oxygen species. Free Radie Res 42;8:725–736. https://doi.org/10.1080/10715760802337265; PMid:18712632

27. Polsani S, Phipps E, Jim B. 2013. Emerging new biomarkers of preeclampsia. Adv. Chronic Kidney Dis. 20(3):271–9. https://doi.org/10.1053/j.ackd.2013.01.001; PMid:23928393

28. Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, Thadhani R. 2007. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension. 50(1):137–42. https://doi.org/10.1161/HYPERTENSIONAHA.107.087700; PMid:17515455

29. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ et al. 2012. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 125(7):911–9. https://doi.org/10.1161/CIRCULATIONAHA.111.054361; PMid:22261192 PMCid:PMC3319742

30. Reddy A, Suri S, Sargent IL, Redman CW, Muttukrishna S. 2009. Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and pre-eclampsia. PLoS One. 4(2):e4453. https://doi.org/10.1371/journal.pone.0004453; PMid:19412349 PMCid:PMC2675175

31. Sánchez-Aranguren LС et all. 2014, October 10. Endothelial dysfunction and preeclampsia: role of oxidative stress. Front. Physiol.

32. Serov VN, Kan NE, Tyutyunik VL. 2016. Prognosticvalue of ratio of soluble fms-like tyrokinase-1 to placental growth factor in pregnant women with preeclampsia. Obstetrics and Gynecology. 6:5–10.

33. Sibai B, Dekker G, Kupferminc M. 2005. Pre-eclampsia. Lancet. 365(9461):785–99. https://doi.org/10.1016/S0140-6736(05)71003-5

34. Sidorova IS, Nikitina NA. 2014. Predictive, preventive approach to the management of pregnancies at risk of pre-eclampsia. Russian vestnik Obstetrics and Gynecology. 5(14):44–49.

35. Staff AC. 2011. Circulating predictive biomarkers in preeclampsia. Pregnancy Hypertens. 1(1):28–42. https://doi.org/10.1016/j.preghy.2010.10.012

36. Staff AC, Benton SJ, von Dadelszen P, Roberts JM, Taylor RN, Powers RW et al. 2013. Redefining preeclampsia using placenta-derived biomarkers. Hypertension. 61(5):932–42. https://doi.org/10.1161/HYPERTENSIONAHA.111.00250; PMid:23460278

37. Staff AC, Braekke K, Harsem NK, Lyberg T, Holthe MR. 2005. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur. J. Obstet. Gynecol. Reprod. Biol. 122(1):33–9. https://doi.org/10.1016/j.ejogrb.2004.11.015; PMid:15935542

38. Stepan H, Geipel A, Schwarz F, Krдmer T, Wessel N, Faber R. 2008. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am. J. Obstet. Gynecol. 198(2):175. e1-6.

39. Thadhani R, Mutter WP, Wolf M et al. 2004. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 89:770–775. https://doi.org/10.1210/jc.2003-031244; PMid:14764795

40. Vatten LJ, Eskild A, Nilsen TI, Jeansson S, Jenum PA, Staff AC. 2007. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am. J. Obstet. Gynecol. 196(3):239–46. https://doi.org/10.1016/j.ajog.2006.10.909; Mid:17346536

41. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P et al. 2014. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 63(2):346–52. https://doi.org/10.1161/HYPERTENSIONAHA.113.01787; PMid:24166751

42. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H. 2010. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am. J. Obstet. Gynecol. 202;2:161.el-161.ell.

43. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG et al. 2010. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am. J. Obstet. Gynecol. 202(2):161. e1-161. e11.

44. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H et al. 2012. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am. J. Obstet. Gynecol. 206(1):58. e1-8.

45. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P et al. 2014. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 63(2):346–52. https://doi.org/10.1161/HYPERTENSIONAHA.113.01787; PMid:24166751

46. Villa PM, Hämäläinen E, Mäki A, Räikkönen K, Pesonen AK, Taipale P et al. 2013. Vasoactive agents for the prediction of early- and late-onset preeclampsia in a high-risk cohort. BMC Pregnancy Childbirth. 13:110. https://doi.org/10.1186/1471-2393-13-110; PMid:23663420 PMCid:PMC3661359

47. Wathen KA, Tuutti E, Stenmun UH, Alfthan H, Halmesmaki E, Finne P, Ylikorkala O, Vuorela P. 2006. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J. Clin Endocrinol Metabol. 91;1:180–184. https://doi.org/10.1210/jc.2005-1076; PMid:16263826

48. Wikström AK, Larsson A, Eriksson UJ, Nash P, Nordén-Lindeberg S, Olovsson M. 2007. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet. Gynecol. 109(6):1368–74. https://doi.org/10.1097/01.AOG.0000264552.85436.a1; PMid:17540809

49. Wortelboer EJ, Koster MP, Cuckle HS, Stoutenbeek PH, Schielen PC, Visser GH. 2010. First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset preeclampsia. BJOG 117;11:1384–1389. https://doi.org/10.1111/j.1471-0528.2010.02690.x; PMid:20840693

50. Xu QS, Liang YZ, Du YP. 2004. Monte Carlo cross-validation for selecting a model and estimating the prediction error in multivariate calibration. J. Chemometrics. 18(2):112–20. https://doi.org/10.1002/cem.858

51. Young ВC, Levine RJ, Karumanchi SA. 2010. Pathogenesis of preeclampsia. Annu Rev Pathol 5:173–192. https://doi.org/10.1146/annurev-pathol-121808-102149; PMid:20078220

52. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstrцm M et al. 2016. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N. Engl. J. Med. 374(1):13–22. https://doi.org/10.1056/NEJMoa1414838; PMid:26735990

53. Zhang J, Klebanoff MA, Roberts JM. 2001. Prediction of adverse outcomes by common definitions of hypertension in pregnancy. Obstet. Gynecol. 97(2):261–7. https://doi.org/10.1016/S0029-7844(00)01125-X; https://doi.org/10.1097/00006250-200102000-00018

Содержание журнала Full text of article